Novel thioamide derivatives as neutral CB1 receptor antagonists

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Obesity Research

Background:

• The cannabinoid-1 (CB1) receptor is a key target for obesity pharmacotherapy.
• Existing CB1 antagonists have faced challenges with side effects and solubility.
• Development of novel, effective, and safe CB1 antagonists is crucial.

Purpose of the Study:

• To synthesize and characterize a novel class of 5,6-diaryl-pyrazine-2-amide derivatives as CB1 receptor antagonists.
• To evaluate the in vitro potency and in vivo efficacy of these compounds for obesity treatment.
• To assess the impact of structural modifications (carboxamide to thioamide) on pharmacological properties.

Main Methods:

• One-pot synthesis was employed to convert carboxamide linkers to thioamides in 5,6-diaryl-pyrazine-2-amide derivatives.
• In vitro CB1 receptor binding assays were performed to determine antagonist potency (IC50 values).
• Solubility of the synthesized compounds was assessed.
• In vivo efficacy was evaluated by administering a lead compound (antagonist 2c) to cafeteria diet-induced obese mice to measure body weight changes.

Main Results:

• A series of 5,6-diaryl-pyrazine-2-amide thioamide derivatives were successfully synthesized.
• These thioamide compounds exhibited potent CB1 receptor antagonism with IC50 values below 10 nM, comparable to parent carboxamides.
• The thioamide modification resulted in improved aqueous solubility compared to the carboxamide analogs.
• The neutral antagonist 2c demonstrated a significant reduction in body weight in diet-induced obese mice.

Conclusions:

• The transformation of carboxamides to thioamides in 5,6-diaryl-pyrazine-2-amide derivatives yields potent CB1 receptor antagonists.
• These novel thioamide antagonists possess enhanced solubility and maintain high CB1 receptor affinity.
• Antagonist 2c represents a promising therapeutic candidate for obesity management due to its efficacy in preclinical models.